Liposomal doxorubicin

Liposomal Doxorubicin is a chemotherapeutic agent used in the treatment of various types of cancer. It is a form of the drug doxorubicin that has been encapsulated in a liposome.

Overview

Doxorubicin is an anthracycline antibiotic that works by intercalating DNA, disrupting the function of enzymes involved in DNA replication and transcription. However, its use is limited by its toxicity, particularly to the heart. Liposomal doxorubicin was developed to reduce this toxicity while maintaining the drug's anti-cancer effects.

Mechanism of Action

Liposomal doxorubicin works in the same way as regular doxorubicin, by intercalating DNA and disrupting the function of topoisomerase II, an enzyme involved in DNA replication and transcription. The liposome encapsulating the doxorubicin is designed to prolong the circulation time of the drug, increase its accumulation in the tumor, and reduce distribution to healthy tissues.

Clinical Use

Liposomal doxorubicin is used in the treatment of various types of cancer, including ovarian cancer, multiple myeloma, and Kaposi's sarcoma. It is also used in the treatment of AIDS-related Kaposi's sarcoma.

Side Effects

Like all chemotherapeutic agents, liposomal doxorubicin has potential side effects. These can include nausea, vomiting, hair loss, and mouth sores. However, it is less likely to cause heart damage compared to regular doxorubicin.

See Also

• Chemotherapy
• Doxorubicin
• Liposome
• Cancer

This Chemotherapy related article is a stub. You can help WikiMD by expanding it.